Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Lupus nephritis
•
Cyclophosphamide
•
Scleroderma
•
SLE
When do you consider Mesna for patients taking oral cyclophosphamide?
What dose do you use? Do you utilize oral or IV infusion Mesna?
Related Questions
How do you guide patients who seek online information about their disease to ensure it is accurate, supports their understanding, and minimizes unnecessary anxiety?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Do you hospitalize patients with newly diagnosed lupus nephritis and nephrotic syndrome if you are able to provide pulse steroids outpatient and follow them closely?
How do you envision incorporating CAR-T therapy into your clinical practice?
How do you manage a pregnant patient with lupus who develops renal disease during pregnancy that is not due to pre-eclampsia?
How do you approach discussing the pill burden of voclosporin with patients who already have to take a regimen such as MMF+HCQ+ACEi and possibly more?
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
